Senate panel seeks middle ground on human fetal tissue research and abortion

first_img A Senate spending panel yesterday countered a move by its House of Representatives counterpart to quash federal funding for research that uses human fetal tissue from elective abortions. The move sets up a conflict that will need to be resolved when lawmakers meet later this year to hash out differences between the House and Senate bills, which will provide funding for the National Institutes of Health (NIH) in the 2018 fiscal year that begins on 1 October.The Senate Appropriations Committee, in a bill that boosts NIH funding by $2 billion, to $36.1 billion, ordered the biomedical research agency to launch a pilot study to determine whether banking tissue from stillbirths and spontaneous abortions, or miscarriages, could serve all of the needs of biomedical researchers. The bill orders NIH to model its program on an NIH initiative that, 25 years ago, sought to assess the quality and quantity of such tissue as a first step in establishing a national network of banks of tissue from spontaneous abortions.How researchers obtain human fetal tissue—which is used to study infectious diseases, eye maladies, normal and abnormal fetal development, and other illnesses—has long been a political flashpoint. Those opposed to abortion have for decades sought to ban the use of federal funds for studies that use fetal tissue obtained from elective abortions. In 1988, President Ronald Reagan placed a de facto moratorium on the use of tissue from elective abortions, which President Bill Clinton lifted in 1993; Congress legalized funding for such research the same year. Senate panel seeks middle ground on human fetal tissue research and abortion Email “The Committee acknowledges the many differing views on the merits of human fetal tissue research,” Senate lawmakers wrote in a report accompanying the 2018 funding bill. As a result, they wrote, their bill “direct[s] NIH to begin a pilot to determine the adequacy of a fetal tissue donor network for supporting all related clinical research.”The Senate language leaves untouched NIH’s ongoing support for research using fetal tissue from elective abortions. The agency expects to spend $107 million on projects using such tissue in the current fiscal year, which ends on 30 September, and $81 million in 2018.In contrast, the House Appropriations Committee passed a spending bill in July that would bar NIH from conducting or funding fetal tissue research “if such tissue is obtained pursuant to an induced abortion.”Some fetal tissue research advocates welcomed the milder Senate language. “This is probably a fair compromise between the people interested in completely banning fetal tissue research and those on the other saying fetal tissue research is still of value,” says Jennifer Zeitzer, the director of legislative relations at the Federation of American Societies for Experimental Biology in Bethesda, Maryland. “This is a tribute to the fact that the Senate committee [charged with NIH appropriations] works in a bipartisan manner but is also very supportive of biomedical research.”Other fetal tissue research advocates were less enthusiastic. “While this is better than the language in the House bill, it is still disappointing,” Sean Tipton, the chief advocacy, policy, and development officer at the American Society for Reproductive Medicine in Washington, D.C., wrote in an email. “We just hope fetal tissue research continues to be performed based on the scientific merits alone, and is not subject to political pressure from Congress.”Opponents of the research were also disappointed. “It’s a very mild or modest step on the Senate side compared to what the House was proposing,” says David Prentice, vice president and research director of the nonprofit Charlotte Lozier Institute in Washington, D.C., which opposes abortion. “It doesn’t foreclose any current research. We would be in favor of that foreclosure.”Whatever resolution House and Senate lawmakers come to won’t be finalized before December at the earliest. Congress this week is expected to approve a continuing resolution that will freeze spending at 2017 levels through 8 December. In the meantime, the House and Senate will try to complete work on their 2018 spending bills, and then reach agreement on final spending levels and related language—such as the fetal tissue research provisions—included in the spending bills. Click to view the privacy policy. Required fields are indicated by an asterisk (*) By Meredith WadmanSep. 8, 2017 , 1:45 PM Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Sign up for our daily newsletter Get more great content like this delivered right to you! Country Wally Gobetz/Flickr (CC BY-NC-ND 2.0) last_img

0 thoughts on “Senate panel seeks middle ground on human fetal tissue research and abortion”

Leave a Reply

Your email address will not be published. Required fields are marked *